RxDoctor Payments Data

June Yin, MD

Neurology · Flushing, NYNPI 1154353332

Payments from drug & device makers

$9,313in general payments, 2019–2025

Across 330 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • UCB, Inc.$746
  • Intuitive Surgical$608
  • Sanofi$514
  • plus $4K from 38 others

What the payments were for

  • Speaking & faculty fees$1151%
  • Travel & lodging$6087%
  • Food & beverage$8,56092%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,313 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$43,253
Medicare patients
130
Services billed
365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Epolamine297$153,966
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5014$92,048
Oxcarbazepine3,515$83,046
NeuproRotigotine57$57,275
Diclofenac Sodium91$32,415
Nortriptyline Hcl4,911$29,592
OngentysOpicapone23$21,796
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone146$18,209
NuedextaDextromethorphan Hbr/Quinidine12$17,623
Quetiapine Fumarate2,616$15,612
Naproxen1,171$13,012
Donepezil Hcl2,073$12,358
Rasagiline Mesylate46$8,108
VascepaIcosapent Ethyl18$6,145
Primidone632$5,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Neupro$746$57,27557 claims
Neurocrine Biosciences, Inc.Ongentys$1,666$21,79623 claims
Avanir Pharmaceuticals, Inc.Nuedexta$14$17,62312 claims
PfizerDilantin$98$2,92320 claims
Lilly USA, LLCOlanzapine$22$54227 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$78$52611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →